ASCO 2018 Roundtable - Lung Cancer - Keynote 042 Trial - Keytruda:Pembrolizumab as a Single Agent Compared to Doublet Chemotherapy for NSCLC

Article and Video CATEGORIES

Cancer Journey

ABOUT

Howard Jack West, MD, Founder, Board President

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

ASCO 2018 Roundtable - Lung Cancer - Keynote 042 Trial - Keytruda (Pembrolizumab) as a Single Agent Compared to Doublet Chemotherapy for NSCLC

dbrock

Sun, 11/04/2018 - 16:10

Author

Howard (Jack) West, MD

Drs. H. Jack West, Medical Director - Thoracic Oncology Program at Swedish Cancer Institute, President and CEO of GRACE, Karen Kelly - Associate Director for Clinical Research at UC Davis Comprehensive Cancer Center, and Sandip Patel - Medical Oncologist and Associate Professor of Medicine at Moores Cancer Center, UC San Diego Health, gathered post meeting to discuss new information from ASCO 2018 regarding lung cancer.

In this roundtable video, the doctors discuss Keytruda (pembrolizumab) as a single agent compared to doublet chemotherapy for NSCLC.

GRACE thanks the following sponsors for their support.

Video Language

English

Please feel free to offer comments and raise questions in our
discussion forums.

Join The conversation

Next Previous link

Previous Post Next Post

Article

The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.